Aegis Maintains Ironwood Pharma (IRWD) at Buy; Still Positive on LINZESS Amid Slower Start

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Aegis Maintains Ironwood Pharma (IRWD) at Buy; Still Positive on LINZESS Amid Slower Start

Ironwood Pharma (IRWD) Posts Q1 Loss of 38c/Share

April 29, 2014 7:06 AM EDT

Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.38), $0.06 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $8.52 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

... More